Amphastar Pharmaceuticals (NASDAQ:AMPH) Cut to Hold at StockNews.com

StockNews.com cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a buy rating to a hold rating in a report issued on Friday morning.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Trading Up 0.4 %

NASDAQ AMPH opened at $50.73 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. Amphastar Pharmaceuticals has a one year low of $36.56 and a one year high of $65.92. The company has a 50-day simple moving average of $48.29 and a 200-day simple moving average of $43.89. The firm has a market capitalization of $2.47 billion, a PE ratio of 16.21, a price-to-earnings-growth ratio of 0.96 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. The firm had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. On average, equities analysts forecast that Amphastar Pharmaceuticals will post 3.7 earnings per share for the current year.

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now owns 33,971 shares in the company, valued at approximately $1,463,130.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at $3,504,256.23. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard K. Prins sold 17,101 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the transaction, the director now owns 33,971 shares in the company, valued at $1,463,130.97. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,101 shares of company stock valued at $1,069,350. Insiders own 27.10% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several large investors have recently bought and sold shares of AMPH. GAMMA Investing LLC increased its holdings in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares during the period. Innealta Capital LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter valued at approximately $55,000. Blue Trust Inc. grew its stake in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after purchasing an additional 309 shares during the period. Asset Management One Co. Ltd. acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after buying an additional 301 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.